Literature DB >> 28691253

Cardiovascular disease risk in patients receiving organ transplantation: a national cohort study.

Hsin-I Tsai1,2,3, Fu-Chao Liu1,2,3, Chao-Wei Lee2,3,4, Chang-Fu Kuo2,5, Lai-Chu See5,6,7, Ting-Ting Chung8, Huang-Ping Yu1,2.   

Abstract

Although organ transplantation is the definitive treatment for end-stage organ failure, the post-transplant outcomes can be substantially influenced by cardiovascular complications. A national cohort study was performed to estimate risks of cardiovascular diseases in those with heart, lung, kidney, and liver transplantation. This cohort study consisted of 5978 solid organ transplantations identified using the Taiwan National Health Insurance Database. Cardiovascular and mortality risks in transplant recipients were evaluated using standardized incidence ratios, excess absolute risks, and standardized mortality ratios as compared to those in the general population. In heart, kidney, and liver recipients, the standardized incidence ratios of overall cardiovascular diseases were 9.41 (7.75-11.44), 3.32 (2.29-3.77), and 1.4 (1.15-1.7) and the overall standardized mortality ratios were 5.23 (4.54-6.03), 1.48 (1.34-1.63), and 3.95 (3.64-4.28), respectively. Except for heart organ recipients who were at highest risk for coronary artery disease with a standardized incidence ratio of 13.12 (10.57-16.29), kidney and liver organ recipients had a ninefold increased risk in developing deep vein thrombosis post-transplant. In conclusion, solid organ transplant patients are at risk of cardiovascular disease, in particular, deep vein thrombosis, which may warrant early identification of high-risk patients in addition to prompt and adequate thromboprophylaxis perioperatively.
© 2017 Steunstichting ESOT.

Entities:  

Keywords:  cohort study; organ transplantation; population study; vascular disease risk

Mesh:

Year:  2017        PMID: 28691253     DOI: 10.1111/tri.13010

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  5 in total

Review 1.  Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations.

Authors:  Manhal Izzy; Brett E Fortune; Marina Serper; Nicole Bhave; Andrew deLemos; Juan F Gallegos-Orozco; Cesar Guerrero-Miranda; Shelley Hall; Matthew E Harinstein; Maria G Karas; Michael Kriss; Nicholas Lim; Maryse Palardy; Deirdre Sawinski; Emily Schonfeld; Anil Seetharam; Pratima Sharma; Jose Tallaj; Darshana M Dadhania; Lisa B VanWagner
Journal:  Am J Transplant       Date:  2022-03-31       Impact factor: 9.369

Review 2.  Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients.

Authors:  Gianluigi Cuomo; Giuseppe Cioffi; Anna Di Lorenzo; Francesca Paola Iannone; Giuseppe Cudemo; Anna Maria Iannicelli; Mario Pacileo; Antonello D'Andrea; Carlo Vigorito; Gabriella Iannuzzo; Francesco Giallauria
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

3.  Myocardial remodeling after kidney transplantation: a case report.

Authors:  Marceli Lukaszewski; Kinga Kosiorowska; Dorota Kaminska; Marta Obremska; Oktawia Mazanowska; Magdalena Krajewska
Journal:  BMC Nephrol       Date:  2018-12-20       Impact factor: 2.388

4.  Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19.

Authors:  Amanda J Vinson; Ran Dai; Gaurav Agarwal; Alfred J Anzalone; Stephen B Lee; Evan French; Amy L Olex; Vithal Madhira; Roslyn B Mannon
Journal:  Am J Transplant       Date:  2021-11-01       Impact factor: 9.369

Review 5.  Dyslipidemia in Transplant Patients: Which Therapy?

Authors:  Gabriella Iannuzzo; Gianluigi Cuomo; Anna Di Lorenzo; Maria Tripaldella; Vania Mallardo; Paola Iaccarino Idelson; Caterina Sagnelli; Antonello Sica; Massimiliano Creta; Javier Baltar; Felice Crocetto; Alessandro Bresciani; Marco Gentile; Armando Calogero; Francesco Giallauria
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.